Methotrexate
Acute Myeloid Leukemia With BCR-ABL1
Explore 12 assets in Acute Myeloid Leukemia With BCR-ABL1 →Floatz Rating
B56/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06401603CT.gov A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT03147612CT.gov Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia With BCR-ABL1
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Methotrexate (this asset) | M.D. Anderson Cancer Center | P2 | B · 56 |
| (+)-Vincristine | M.D. Anderson Cancer Center | P2 | B |
| Blinatumomab | M.D. Anderson Cancer Center | P2 | B |
| Cytarabine | M.D. Anderson Cancer Center | P2 | B |
| Ponatinib | M.D. Anderson Cancer Center | P2 | CCC |
| Pegfilgrastim | M.D. Anderson Cancer Center | P2 | CCC |
| Rituximab | M.D. Anderson Cancer Center | P2 | CCC |
| Cyclophosphamide | M.D. Anderson Cancer Center | P2 | CCC |
| Nivestim | M.D. Anderson Cancer Center | P2 | CCC |
+3 more in the Acute Myeloid Leukemia With BCR-ABL1 cohort
Other indications for Methotrexate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Acute Promyelocytic Leukemia | — | P3 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Methotrexate in Acute Myeloid Leukemia With BCR-ABL1. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/methotrexate-acute-myeloid-leukemia-with-bcr-abl1
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →